Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

    NEXT STORY
    ADMA Biologics Announces Pricing of Public Offering of Common Stock
    PREV STORY
    Terveystalo’s network of occupational health services to expand: Terveystalo to acquire Työsyke Oy in Kanta-Häme
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Kantar Health Launches New Oncology Platform, Allowing Healthcare Companies to Better Understand Drug Opportunities

    NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Kantar Health, a leading global healthcare ...

    author_avatar
    NASDAQ Market News

    Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research (AACR) Epigenetics Conference

    Effect of rigosertib plus azacitidine treatment on epigenetic modulation in cancer cell-lines and patient ...

    author_avatar
    NASDAQ Market News

    AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide

    WALTHAM, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced ...

    author_avatar
    NASDAQ Market News